Rebecca Hung, MD
Cardiovascular Disease · Nashville, TNNPI 1134203243
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,393 of the $40,311 with a category attached, or 60.5%. 8 manufacturers reported payments, led by Bridgebio Pharma, Inc. at 39.8% of the total. Among cardiovascular disease clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 37 payments — averaging $1089.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bridgebio Pharma, Inc.$16K
- Pfizer$9K
- Alnylam Pharmaceuticals Inc.$7K
- Akcea Therapeutics, Inc.$6K
- AstraZeneca$2K
- Novo Nordisk$78
- plus $43 from 2 others
Across 96 payments — averaging $18,606 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$1.7M
- Ionis Pharmaceuticals, Inc.$64K
What the payments were for
- Consulting fees$24,39361%
- Travel & lodging$14,64436%
- Food & beverage$1,2743%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bridgebio Pharma, Inc. | 3 | $16,043 |
| Pfizer | 5 | $9,477 |
| Alnylam Pharmaceuticals Inc. | 8 | $6,702 |
| Akcea Therapeutics, Inc. | 12 | $6,326 |
| AstraZeneca | 5 | $1,642 |
| Novo Nordisk | 1 | $78 |
| Novartis | 2 | $29 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,311 in reported general payments places this provider in the 90th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 531 | $13,175,656 |
| WainuaEplontersen Sodium | 55 | $2,315,724 |
| EntrestoSacubitril/Valsartan | 465 | $650,224 |
| JardianceEmpagliflozin | 350 | $511,392 |
| EliquisApixaban | 335 | $487,000 |
| FarxigaDapagliflozin Propanediol | 357 | $465,101 |
| Droxidopa | 46 | $211,629 |
| CamzyosMavacamten | 26 | $207,152 |
| OzempicSemaglutide | 101 | $91,340 |
| Repatha SureclickEvolocumab | 89 | $85,879 |
| XareltoRivaroxaban | 37 | $47,334 |
| Praluent PenAlirocumab | 30 | $25,001 |
| CorlanorIvabradine Hcl | 21 | $20,968 |
| Eplerenone | 178 | $20,343 |
| WegovySemaglutide | 12 | $15,926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $9,477 | $13,662,656866 claims |
| AstraZenecaWainua, Farxiga | $1,642 | $2,780,825412 claims |
| NovartisEntresto | $29 | $650,224465 claims |
| Boehringer IngelheimJardiance | $14 | $511,392350 claims |
| Novo NordiskOzempic, Wegovy | $78 | $107,266113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Nashville
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Andrew ZurickNashville$231K
- Mark ZenkerNashville$225K
- George CrossleyNashville$197K
- Joel PharesNashville$171K
- Arvindh KanagasundramNashville$161K
- Jessica HustonNashville$109K
- Joshua BeckmanNashville$106K
- Travis RichardsonNashville$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.